Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie-Christine Etienne-Grimaldi

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 3, 2009
A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasmaMarie-Christine Etienne-Grimaldi, Nicole Renée, Hassan Izzedine, et al.
Cancer Treatment Reviews|March 6, 2012
The impact of pharmacogenetics on radiation therapy outcome in cancer patients. A focus on DNA damage response genesDelphine Borchiellini, Marie-Christine Etienne-Grimaldi, Juliette Thariat, et al.
Pharmacogenomics|November 24, 2007
Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancerMarie-Christine Etienne-Grimaldi, Mireille Francoual, Jean-Louis Formento, et al.
Current Opinion in Oncology|March 26, 2023
Chemotherapy postimmunotherapy for recurrent metastatic head and neck squamous cell carcinomaAgnes Ducoulombier, Joel Guigay, Marie-Christine Etienne-Grimaldi, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|June 20, 2008
Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolitesThierry Besnard, Nicole Renée, Marie-Christine Etienne-Grimaldi, et al.
Anti-Cancer Drugs|October 30, 2004
Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytesJean-Louis Fischel, Patricia Formento, Joseph Ciccolini, et al.
Oral Oncology|February 17, 2010
Tapered dose versus constant drug exposure to anti-EGFR drugs on head-and-neck cancer xenografts. A comparison between cetuximab and gefitinibAlexandre Bozec, Patricia Formento, Jean-Louis Fischel, et al.
Oral Oncology|August 25, 2011
Antitumor activity of cetuximab associated with the taxotere-cisplatin-fluorouracil (TPF) combination on an orthotopic head and neck cancer modelAlexandre Bozec, Anne Sudaka, Marie-Christine Etienne-Grimaldi, et al.
British Journal of Clinical Pharmacology|March 6, 2007
Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicityNicolas Magné, Marie-Christine Etienne-Grimaldi, Laurent Cals, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2004
Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumabPatricia Formento, Jean-Michel Hannoun-Levi, Jean-Louis Fischel, et al.
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 3, 2009
A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasmaMarie-Christine Etienne-Grimaldi, Nicole Renée, Hassan Izzedine, et al.
Cancer Treatment Reviews|March 6, 2012
The impact of pharmacogenetics on radiation therapy outcome in cancer patients. A focus on DNA damage response genesDelphine Borchiellini, Marie-Christine Etienne-Grimaldi, Juliette Thariat, et al.
Pharmacogenomics|November 24, 2007
Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancerMarie-Christine Etienne-Grimaldi, Mireille Francoual, Jean-Louis Formento, et al.
Current Opinion in Oncology|March 26, 2023
Chemotherapy postimmunotherapy for recurrent metastatic head and neck squamous cell carcinomaAgnes Ducoulombier, Joel Guigay, Marie-Christine Etienne-Grimaldi, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|June 20, 2008
Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolitesThierry Besnard, Nicole Renée, Marie-Christine Etienne-Grimaldi, et al.
Anti-Cancer Drugs|October 30, 2004
Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytesJean-Louis Fischel, Patricia Formento, Joseph Ciccolini, et al.
Oral Oncology|February 17, 2010
Tapered dose versus constant drug exposure to anti-EGFR drugs on head-and-neck cancer xenografts. A comparison between cetuximab and gefitinibAlexandre Bozec, Patricia Formento, Jean-Louis Fischel, et al.
Oral Oncology|August 25, 2011
Antitumor activity of cetuximab associated with the taxotere-cisplatin-fluorouracil (TPF) combination on an orthotopic head and neck cancer modelAlexandre Bozec, Anne Sudaka, Marie-Christine Etienne-Grimaldi, et al.
British Journal of Clinical Pharmacology|March 6, 2007
Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicityNicolas Magné, Marie-Christine Etienne-Grimaldi, Laurent Cals, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2004
Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumabPatricia Formento, Jean-Michel Hannoun-Levi, Jean-Louis Fischel, et al.
Pageof 7